University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Neil Shah, MD, PhD

Neil Shah, MD, PhD

Professor, Department of Medicine (Hematology/Oncology), UCSF
Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center
Edward S. Ageno Distinguished Professorship in Hematology/Oncology, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Research Summary

My research program has been highly focused on identifying and overriding molecular mechanisms of resistance to targeted therapeutics in hematopoietic malignancies, and is highly translational in nature. I therefore rely heavily upon HDFCCC infrastructure, including the Phase I Unit in the Developmental Therapeutics Program, the Tissue Core, the Bioinformatics Core, and the Mouse Therapeutics Core Facility. Additionally, I have ongoing Intra- and Inter-Programmatic collaborations with numerous Members and Associate Members, including Benjamin Braun, Emmanuelle Passegue, Scott Kogan, Mignon Loh, and Kevan Shokat.

Education

University of California, Berkeley, BS,1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine


Professional Experience

  • 1984-1987
    Staff Research Associate, University of California, Los Angeles (UCLA), laboratory of Irvin S.-Y. Chen
  • 1987-1992
    Graduate Student Researcher, UCLA, laboratory of Owen N. Witte
  • 1996-1998
    Internship and Residency, UCLA School of Medicine
  • 1998-2000
    Clinical part of Fellowship in Hematology/Oncology, UCLA School of Medicine
  • 2000-2003
    Postdoctoral Fellow, UCLA, laboratory of Charles L. Sawyers
  • 2003-2004
    Clinical Instructor, Division of Hematology/Oncology, UCLA School of Medicine
  • 2004-2006
    Visiting Assistant Professor, Division of Hematology/Oncology, UCLA School of Medicine
  • 2006-2013
    Assistant Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine
  • 2013-2017
    Associate Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine
  • 2017-present
    Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine

Honors & Awards

  • 1989-1991
    National Institutes of Health Predoctoral Award in Tumor Cell Biology
  • 1995
    Alpha Omega Alpha Medical Student Research Prize
  • 1995-2003
    UCLA Specialty Training and Advanced Research (STAR) Award
  • 2001-2004
    Leukemia and Lymphoma Society Career Development Award for Fellows
  • 2003-2005
    NIH K12 Award in Clinical Pharmacology
  • 2004-2007
    Leukemia and Lymphoma Society Career Development Award for Special Fellows
  • 2006-2009
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2009-2014
    Leukemia and Lymphoma Society Scholar in Clinical Research Award

Selected Publications

  1. Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Ann Hematol. 2017 Aug; 96(8):1303-1313.
    View on PubMed
  2. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 12; 14(12):1505-1512.
    View on PubMed
  3. Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74.
    View on PubMed
  4. Wauters L, Brown T, Venter C, Dziubak R, Meyer R, Brogan B, Walsh J, Fox AT, Shah N. Cow's Milk Allergy Prescribing Is Influenced by Regional and National Guidance. J Pediatr Gastroenterol Nutr. 2016 05; 62(5):765-70.
    View on PubMed
  5. Trifiletti DM, Lee CC, Shah N, Patel NV, Chen SC, Sheehan JP. How Does Brainstem Involvement Affect Prognosis in Patients with Limited Brain Metastases? Results of a Matched-Cohort Analysis. World Neurosurg. 2016 Apr; 88:563-8.
    View on PubMed
  6. Apsel Winger B, Shah NP. PPARγ: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015 Oct 12; 28(4):409-411.
    View on PubMed
  7. Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep. 2015 Sep 30; 5:14538.
    View on PubMed
  8. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun; 5(6):668-79.
    View on PubMed
  9. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20; 9(4):1333-48.
    View on PubMed
  10. Tajon CA, Seo D, Asmussen J, Shah N, Jun YW, Craik CS. Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia. ACS Nano. 2014 Sep 23; 8(9):9199-208.
    View on PubMed
  11. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22.
    View on PubMed
  12. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View on PubMed
  13. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb; 95(2):232-40.
    View on PubMed
  14. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010 Jun; 34(6):708-13.
    View on PubMed
  15. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47.
    View on PubMed
  16. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009 Mar 15; 69(6):2384-92.
    View on PubMed
  17. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008 Dec 09; 14(6):485-93.
    View on PubMed
  18. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 01; 26(19):3204-12.
    View on PubMed
  19. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
    View on PubMed
  20. Shah NP. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S31-S36.
    View on PubMed

Go to UCSF Profiles, powered by CTSI